Global Cancer Respiratory Biopsy Market Growth (Status and Outlook) 2025-2031

The global Cancer Respiratory Biopsy market size is predicted to grow from US$ 411 million in 2025 to US$ 1270 million in 2031; it is expected to grow at a CAGR of 20.7% from 2025 to 2031.

Cancer respiratory biopsy is a non-invasive diagnostic technique that detects cancer by analyzing volatile organic compounds (VOCs) or other biomarkers in a patient's exhaled breath. These biomarkers may be generated by tumor metabolic activity and excreted through respiration.

Compared to traditional tissue biopsies such as puncture or bronchoscopy biopsy, respiratory biopsy has advantages such as non invasiveness, convenience, and strong reproducibility, especially suitable for early screening and monitoring of respiratory diseases such as lung cancer.

The detection methods usually involve techniques such as mass spectrometry, gas chromatography-mass spectrometry (GC-MS), sensors, etc.

In recent years, the global cancer respiratory biopsy market has maintained a growth trend. The increase in incidence rate of cancer (especially lung cancer), minimally invasive trend, technological progress and policy support are the main driving factors.

Lung cancer is one of the cancers with the highest incidence in the world and China, which has promoted the demand for early non-invasive detection technology.

Compared to traditional cancer biopsies, respiratory biopsies are safer and more widely accepted by patients.

AI assisted analysis, improved sensor sensitivity, and multimodal image fusion (such as combining CT or MRI) have enhanced the accuracy of respiratory biopsy.

In addition, early screening for cancer has been included in some countries' medical insurance, reducing the burden on patients and promoting the popularization of technology.

The main participants include international companies such as:

• Owlstone Medical
• Breath Diagnostics
• Menssana Research
• Sensigent
• Alpha Szenszor
• NanoScent
• Spira Innovation
• Syft Technologies
• Breathe Biomedical
• Vocxi Health

As well as domestic companies such as:

• BREAX Biotech
• ChromX Health
• Sunvou Medical
• MaiAoTech
• Hanon Instruments
• WIM Spirare

The main challenges facing the market include technological maturity, insufficient standardization, cost and promotion issues.

The sensitivity and specificity of respiratory biopsy still need to be optimized and have not yet become the clinical gold standard.

And there are significant differences in the biomarkers of different detection methods, lacking a unified standard.

High research and development costs and equipment investment may limit the popularization of primary healthcare institutions.

In the future, intelligence, portable devices, and multi cancer detection will be the main development trends in the industry.

AI and machine learning will be used for real-time analysis of respiratory data to improve diagnostic efficiency. The development of miniaturized and wireless detection equipment will facilitate the use of community hospitals.

In addition to lung cancer, companies will also expand their research into respiratory biomarkers for other cancers such as gastric cancer and colorectal cancer.